HER2 in well differentiated breast cancer

Is testing necessary?

G. Kenneth Haines, Elizabeth Wiley, Barbara Susnik, Sophia K. Apple, Snjezana Frkovic-Grazio, Carolina Reyes, Lynn C. Goldstein, Farnaz Dadmanesh, Allen M. Gown, Mehrdad Nadji, Matej Bracko, Fattaneh A. Tavassoli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: In addition to providing a timely and accurate diagnosis, pathologists routinely provide prognostic and predictive information to assist in the treatment of patients with invasive breast cancer. As our understanding of breast cancer at the molecular and genetic level improves, sophisticated new treatment options have become available to patients. The demonstrated improvements in disease-free and overall survival with the use of trastuzumab (Herceptin) has made HER2 testing a standard of care in the evaluation of patients with breast cancer. Specialized breast centers have accumulated sufficient experience to recognize that HER2 positive tumors tend to be of higher grade and to be estrogen receptor negative, whereas well-differentiated breast cancers rarely are HER2 positive. Methods: To determine whether HER2 testing is necessary in well-differentiated breast cancer, we analyzed the frequency of HER2 positivity among 1,162 cases from 7 major breast centers or commercial laboratories in the United States and Europe. Results; Well-differentiated breast cancers, defined by either nuclear grading or the Scarff-Bloom-Richardson system, rarely are HER2 positive (mean 1.6%, range 0-2.8%). Conclusions: Given the low rate of well differentiated HER2 positive tumors, falling within the range reported for false negative IHC tests for HER2, and the absence of published data demonstrating a beneficial effect of trastuzumab therapy in this subset of patients, HER2 testing should not be considered a standard of care for all patients with well-differentiated breast cancer.

Original languageEnglish
Pages (from-to)551-556
Number of pages6
JournalBreast Cancer Research and Treatment
Volume112
Issue number3
DOIs
StatePublished - Dec 1 2008

Fingerprint

Breast Neoplasms
Standard of Care
Breast
Estrogen Receptors
Disease-Free Survival
Molecular Biology
Neoplasms
Therapeutics
Trastuzumab

Keywords

  • Breast cancer
  • FISH
  • HER2
  • Immunohistochemistry
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Haines, G. K., Wiley, E., Susnik, B., Apple, S. K., Frkovic-Grazio, S., Reyes, C., ... Tavassoli, F. A. (2008). HER2 in well differentiated breast cancer: Is testing necessary? Breast Cancer Research and Treatment, 112(3), 551-556. https://doi.org/10.1007/s10549-008-9893-8

HER2 in well differentiated breast cancer : Is testing necessary? / Haines, G. Kenneth; Wiley, Elizabeth; Susnik, Barbara; Apple, Sophia K.; Frkovic-Grazio, Snjezana; Reyes, Carolina; Goldstein, Lynn C.; Dadmanesh, Farnaz; Gown, Allen M.; Nadji, Mehrdad; Bracko, Matej; Tavassoli, Fattaneh A.

In: Breast Cancer Research and Treatment, Vol. 112, No. 3, 01.12.2008, p. 551-556.

Research output: Contribution to journalArticle

Haines, GK, Wiley, E, Susnik, B, Apple, SK, Frkovic-Grazio, S, Reyes, C, Goldstein, LC, Dadmanesh, F, Gown, AM, Nadji, M, Bracko, M & Tavassoli, FA 2008, 'HER2 in well differentiated breast cancer: Is testing necessary?', Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 551-556. https://doi.org/10.1007/s10549-008-9893-8
Haines GK, Wiley E, Susnik B, Apple SK, Frkovic-Grazio S, Reyes C et al. HER2 in well differentiated breast cancer: Is testing necessary? Breast Cancer Research and Treatment. 2008 Dec 1;112(3):551-556. https://doi.org/10.1007/s10549-008-9893-8
Haines, G. Kenneth ; Wiley, Elizabeth ; Susnik, Barbara ; Apple, Sophia K. ; Frkovic-Grazio, Snjezana ; Reyes, Carolina ; Goldstein, Lynn C. ; Dadmanesh, Farnaz ; Gown, Allen M. ; Nadji, Mehrdad ; Bracko, Matej ; Tavassoli, Fattaneh A. / HER2 in well differentiated breast cancer : Is testing necessary?. In: Breast Cancer Research and Treatment. 2008 ; Vol. 112, No. 3. pp. 551-556.
@article{d2bb9642051149338d0eead7665a0c15,
title = "HER2 in well differentiated breast cancer: Is testing necessary?",
abstract = "Background: In addition to providing a timely and accurate diagnosis, pathologists routinely provide prognostic and predictive information to assist in the treatment of patients with invasive breast cancer. As our understanding of breast cancer at the molecular and genetic level improves, sophisticated new treatment options have become available to patients. The demonstrated improvements in disease-free and overall survival with the use of trastuzumab (Herceptin) has made HER2 testing a standard of care in the evaluation of patients with breast cancer. Specialized breast centers have accumulated sufficient experience to recognize that HER2 positive tumors tend to be of higher grade and to be estrogen receptor negative, whereas well-differentiated breast cancers rarely are HER2 positive. Methods: To determine whether HER2 testing is necessary in well-differentiated breast cancer, we analyzed the frequency of HER2 positivity among 1,162 cases from 7 major breast centers or commercial laboratories in the United States and Europe. Results; Well-differentiated breast cancers, defined by either nuclear grading or the Scarff-Bloom-Richardson system, rarely are HER2 positive (mean 1.6{\%}, range 0-2.8{\%}). Conclusions: Given the low rate of well differentiated HER2 positive tumors, falling within the range reported for false negative IHC tests for HER2, and the absence of published data demonstrating a beneficial effect of trastuzumab therapy in this subset of patients, HER2 testing should not be considered a standard of care for all patients with well-differentiated breast cancer.",
keywords = "Breast cancer, FISH, HER2, Immunohistochemistry, Trastuzumab",
author = "Haines, {G. Kenneth} and Elizabeth Wiley and Barbara Susnik and Apple, {Sophia K.} and Snjezana Frkovic-Grazio and Carolina Reyes and Goldstein, {Lynn C.} and Farnaz Dadmanesh and Gown, {Allen M.} and Mehrdad Nadji and Matej Bracko and Tavassoli, {Fattaneh A.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s10549-008-9893-8",
language = "English",
volume = "112",
pages = "551--556",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - HER2 in well differentiated breast cancer

T2 - Is testing necessary?

AU - Haines, G. Kenneth

AU - Wiley, Elizabeth

AU - Susnik, Barbara

AU - Apple, Sophia K.

AU - Frkovic-Grazio, Snjezana

AU - Reyes, Carolina

AU - Goldstein, Lynn C.

AU - Dadmanesh, Farnaz

AU - Gown, Allen M.

AU - Nadji, Mehrdad

AU - Bracko, Matej

AU - Tavassoli, Fattaneh A.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: In addition to providing a timely and accurate diagnosis, pathologists routinely provide prognostic and predictive information to assist in the treatment of patients with invasive breast cancer. As our understanding of breast cancer at the molecular and genetic level improves, sophisticated new treatment options have become available to patients. The demonstrated improvements in disease-free and overall survival with the use of trastuzumab (Herceptin) has made HER2 testing a standard of care in the evaluation of patients with breast cancer. Specialized breast centers have accumulated sufficient experience to recognize that HER2 positive tumors tend to be of higher grade and to be estrogen receptor negative, whereas well-differentiated breast cancers rarely are HER2 positive. Methods: To determine whether HER2 testing is necessary in well-differentiated breast cancer, we analyzed the frequency of HER2 positivity among 1,162 cases from 7 major breast centers or commercial laboratories in the United States and Europe. Results; Well-differentiated breast cancers, defined by either nuclear grading or the Scarff-Bloom-Richardson system, rarely are HER2 positive (mean 1.6%, range 0-2.8%). Conclusions: Given the low rate of well differentiated HER2 positive tumors, falling within the range reported for false negative IHC tests for HER2, and the absence of published data demonstrating a beneficial effect of trastuzumab therapy in this subset of patients, HER2 testing should not be considered a standard of care for all patients with well-differentiated breast cancer.

AB - Background: In addition to providing a timely and accurate diagnosis, pathologists routinely provide prognostic and predictive information to assist in the treatment of patients with invasive breast cancer. As our understanding of breast cancer at the molecular and genetic level improves, sophisticated new treatment options have become available to patients. The demonstrated improvements in disease-free and overall survival with the use of trastuzumab (Herceptin) has made HER2 testing a standard of care in the evaluation of patients with breast cancer. Specialized breast centers have accumulated sufficient experience to recognize that HER2 positive tumors tend to be of higher grade and to be estrogen receptor negative, whereas well-differentiated breast cancers rarely are HER2 positive. Methods: To determine whether HER2 testing is necessary in well-differentiated breast cancer, we analyzed the frequency of HER2 positivity among 1,162 cases from 7 major breast centers or commercial laboratories in the United States and Europe. Results; Well-differentiated breast cancers, defined by either nuclear grading or the Scarff-Bloom-Richardson system, rarely are HER2 positive (mean 1.6%, range 0-2.8%). Conclusions: Given the low rate of well differentiated HER2 positive tumors, falling within the range reported for false negative IHC tests for HER2, and the absence of published data demonstrating a beneficial effect of trastuzumab therapy in this subset of patients, HER2 testing should not be considered a standard of care for all patients with well-differentiated breast cancer.

KW - Breast cancer

KW - FISH

KW - HER2

KW - Immunohistochemistry

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=56549129621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56549129621&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-9893-8

DO - 10.1007/s10549-008-9893-8

M3 - Article

VL - 112

SP - 551

EP - 556

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -